This report builds on interviews with industry executives, case studies, and analysis of deal and other market data to set out a set of strategies to optimally partner for enhanced drug delivery products.
Features and benefits
Learn from interviews with senior drug delivery partnering executives.
Develop effective partnering strategies based on case studies and analysis of market data.
Unlock therapeutic value of new biopharmaceutical developments by strategic collaborations for innovative drug delivery technologies.
Optimise value from drug delivery partnerships to deliver successful differentiation from novel drug delivery applications.
Understand current and future trends in drug delivery deal-making in order to plan effective partnering strategy.
No single drug delivery partnership model can be applied across all drug delivery partnerships. Partnering around drug delivery technology can occur at different stages of the drug development and commercialization lifecycle, requiring varying levels of collaboration and involving multiple different partners and their respective interests.
The degree of intended collaboration between drug delivery technology partners has declined over the past five years. Big pharma has become an increasingly important source for high value licensing investment in novel drug delivery technologies.
Your key questions answered
How is the drug delivery partnering landscape changing and how will this affect future deal-making?
What are the key strategic contexts for effective drug delivery partnering and how do these impact on deal parameters?
What are the critical success factors involved in lifecycle management deal-making for drug delivery technology?
What are the key challenges involved with making effective drug delivery partnerships for novel drug delivery applications?
How do best practices for drug delivery partnerships differ by the degree to which the delivery component of a drug contributes to its overall value?
Contains 101 pages